Artificial Intelligence
Lila Sciences
30-Second Executive Brief
Executive Assessment
Lila Sciences functions as a regional institution within Artificial Intelligence, backed by 63% sourcing coverage, with accelerating strategic relevance.
- Maintains 3 mapped relationships across the graph
- 63% sourcing coverage across sourced relationships
- Tracked as regional institution within the Artificial Intelligence category
Executive Snapshot
- Strategic Role
- Regional Institution
- Sourcing Coverage
- 63%
- Ecosystem Influence
- Moderate
- Strategic Momentum
- Accelerating
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 3
- Technology Domains
- 4
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
A Flagship Pioneering-incubated startup building AI-driven 'science factories' -- autonomous, closed-loop research platforms spanning life sciences, chemistry and materials science -- under a stated mission to build 'scientific superintelligence.' Lila Sciences emerged from stealth in March 2025 with $200 million in seed capital, later raised a $350 million Series A, and added a $115 million extension in October 2025 including participation from NVIDIA's venture arm, bringing total funding past $550 million at a valuation exceeding $1.3 billion.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
2 sources
- CNBC — Lila Sciences ranks No. 25 on CNBC Disruptor 50, replicates 5-year CAR-T result in 6 monthsnews
- Yahoo Finance / Fierce Biotech — Lila Sciences tops $1.3B valuation with NVIDIA-backed extensionnews
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Lila Sciences — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
The CAR-T replication result gives Lila Sciences a rare concrete, verifiable proof point most AI-for-science peers lack
30% confidenceLila Sciences' AI Science Factory platform replicated a five-year, over-$100-million biotech CAR-T therapy development result in roughly six months using a two-to-three-person team, ranking No. 25 on CNBC's 2026 Disruptor 50 list.
This is InsightNodes' own interpretive read: a small two-to-three-person team matching or exceeding a five-year, $100-million-plus biotech R&D effort in roughly six months is a specific, falsifiable, third-party-comparable claim -- unlike much of the AI-for-science category's more abstract 'scientific superintelligence' framing, this result gives outside observers a concrete basis to evaluate whether the platform genuinely accelerates discovery, which is a meaningfully stronger credibility signal than funding size or valuation alone, even though operating across multiple scientific domains simultaneously still carries real focus and execution risk.
InsightNodes analysis of Lila Sciences' CAR-T replication result · Aug 14, 2026
Lila Sciences's Timeline
A sourced, dated history of Lila Sciences's key moments — founding to present.
Mar 2025 · Emerges from stealth with $200M
Lila Sciences emerged from stealth with $200 million in seed capital to build 'AI science factories' spanning life sciences, chemistry and materials science.
Oct 2025 · Tops $1.3B valuation with NVIDIA-backed extension
Lila Sciences raised a $350 million Series A and a further $115 million extension including NVIDIA's venture arm, bringing total funding past $550 million at a valuation exceeding $1.3 billion.
May 2026 · Ranks No. 25 on CNBC Disruptor 50; replicates 5-year biotech result in 6 months
Lila Sciences ranked No. 25 on CNBC's 2026 Disruptor 50 list; a team of two to three people using Lila's AI Science Factory platform built a complete in vivo CAR-T therapy -- including binder design, mRNA engineering and lipid nanoparticle formulation -- in roughly six months, matching or exceeding results that took biotech Capstan Therapeutics five years and over $100 million using traditional research methods.